Study record
Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes
Knoop A, Thomas A, Thevis M · Rapid Commun Mass Spectrom · 2019
AnalyticalSeveralEvidence tier D
What this study reported
Developed and validated an LC/MS method for MOTS-c in human plasma according to WADA laboratory standards, including in-vitro metabolites and oxidation products. Endogenous MOTS-c levels measured by ELISA in the reference population could not be confirmed by LC/MS, and considerable differences between the two methods were observed.
Limitations
Small reference population; the discrepancy with ELISA leaves true endogenous plasma concentrations unresolved.
Study record
| Study model | Analytical / methods |
|---|---|
| Substance studied | SeveralMore than one of these is central to the paper (common for reviews). |
| Species | human |
| System studied | LC/MS assay for MOTS-c in human plasma for doping control, compared with a commercial ELISA |
| Population | healthy reference subjects |
| Design | Mass-spectrometry assay development and validation |
| Sample size as reported | 20 healthy subjects (ELISA reference population) |
| Control group | Not reported |
| Route (data field only) | Not reported |
| Endpoints measured | assay specificity and sensitivity; lower limit of detection; peptide stability and in-vitro metabolites; LC/MS versus ELISA agreement |
| Pathways measured | Not reported |
| Research areas | Methods |
| Evidence tier | D — Cell, tissue or analytical |
| Publication types | Journal Article, Validation Study |
Appraisal
Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.
- Relevance to MOTS-c
- Direct
- Model applicability
- Human
- Sample size
- Small
- Controls
- n/a
- Outcome validity
- Validated biomarker
- Support for its own conclusion
- Strong
Provenance
- Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
- Annotated from the published abstract.
- Editorial review: approved (2026-11-11).
- Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.